Neuromodulation : journal of the International Neuromodulation Society
-
Evaluate the benefit of intrathecal baclofen (ITB) therapy on function, quality of life, and progression in patients with multiple system atrophy (MSA). ⋯ Our results suggest that ITB can maintain (or improve function) and maintain quality of life in patients with MSA. ITB is currently not indicated for patients with MSA but should be studied further for the quality of life benefits and delay in disease progression it potentially provides.
-
The goal of the study was to assess the efficacy of interaction between spinal cord stimulation (SCS) and peripheral nerve field stimulation (PNFS) and to evaluate a new spinal-peripheral neuromodulation method for low back pain. ⋯ Simultaneous use of SCS and PNFS increase efficacy of both methods for axial back pain. The new SPN method showed great potential in providing coverage for back pain.
-
Non-psychological parameters may predict pump success. ⋯ Trial dose, age, and partially pain location are good predictors of pain relief.
-
Spinal cord stimulator (SCS) infections are common (2.5-13%) and may cause harm. It is unclear if a screening trial with definitive leads presents an increased infection risk. ⋯ Our infection rate (4.8%) compared favorably with our previous survey (7.5%). The reduced number of SCS infections is likely to be due to: strict asepsis, double layer hydrocolloid dressing during the trial, prophylactic antibiotics, operator experience, and patient education. Two-stage procedures with extended trials do not seem to increase the incidence of SCS infections.
-
Case Reports
Bilateral subdural hematoma following implantation of intrathecal drug delivery device.
To report a case of bilateral subacute subdural hematoma following implantation of intrathecal drug delivery device. ⋯ Medical and nursing staff dealing with intrathecal therapy should be aware of this potentially severe complication.